Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
BIOLOGIC LICENSE APPLICATION FOR OT-702 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that biologic license application (BLA) for OT-702 (Aflibercept Intravitreous Injection, EYLEA® biosimilar) has been accepted by the Center for Drug Evaluation ("**CDE**") of the National Medical Products Administration of the People's Republic of China (the "**PRC**") recently.

OT-702 was co-developed by the Group and its partner Shandong Boan Biotechnology Co., Ltd. (山東博安生物技術股份有限公司) ("**Boan Bio**"), the shares of which are listed on The Stock Exchange of Hong Kong Limited (stock code: 6955). Pursuant to the cooperation and exclusive promotion agreement entered into by both parties in October 2020, the Group, together with Boan Bio, shall co-advance the phase III clinical trial of OT-702, and the Group was granted the exclusive right to promote and commercialize the product in the PRC.

OT-702, as a soluble trapping receptor, can bind to cytokines such as VEGF-A, VEGF-B and P1GF, inhibit the downstream signaling pathway of VEGFR, inhibit neovascularization, and reduce vascular permeability, thereby treating pathological neovascularization of the retina and choroid eye diseases. OT-702 is a biosimilar to EYLEA®, the globally approved indications of which include neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), diabetic retinopathy (DR), myopic choroidal neovascularization (mCNV) and retinopathy of prematurity (ROP). According to Technical Guidelines for Similarity Evaluation and Indication Extrapolation of Biosimilars (《生物類似藥相似性評價和適應症外推技術指導原則》) issued by CDE, OT-702 is eligible to apply for approval for all indications approved for EYLEA® in the PRC.

The completed pre-clinical head-to-head comparison study of OT-702 to EYLEA® (Aflibercept Intravitreous Injection) showed OT-702 shared a high degree of similarity in both physical and chemical properties and biological activities with EYLEA®. The results of the phase I clinical trial of OT-702 showed that the safety and tolerability of OT-702 demonstrated in the trial group were consistent with and comparable to those of the original reference drug demonstrated in the original reference drug group. The phase III clinical trial of OT-702, a randomized, double-blind, parallel-controlled and multicenter clinical study to compare the efficacy and safety of OT-702 to EYLEA® in the treatment of wet age-related macular degeneration, was completed in April 2024. The results of the phase III clinical trial demonstrated clinically significant improvement in the eye's best corrected visual acuity (BCVA) under study at weeks 4, 8, 12, 16, 20 and 24 compared with the baseline (by using the early treatment of diabetic retinopathy study (ETDRS) visual acuity chart) for the patients in both trial group and original reference drug group. The therapeutic effectiveness of OT-702 and the original reference drug is highly comparable, where the onset of action of both is rapid and lasting, signifying the fulfillment of all clinical trial endpoints.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-702 (Aflibercept Intravitreous Injection, EYLEA® biosimilar) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, July 16, 2024

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.